Trading Illumina Inc.
Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conference and invited investors to participate via webcast.
UBS Genomics 2.0 and
Illumina, Inc. (Nasdaq:ILMN). The power to make bigger discoveries is here with the launch of NovaSeqTM 6000 v1.5 Reagent Kit. The new NovaSeq 6000 v1.5 Reagent Kits aim to make whole genome
Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the second quarter of fiscal year 2020.
Second quarter 2020 results reflect the impact of the global COVID-19 pandemic:
Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for the second quarter 2020 following the close of market on Thursday, August 6, 2020.
On the same day, at 2:00 pm Pacific
Illumina, Inc. (NASDAQ: ILMN) is bringing turn-key data analysis solutions to accelerate and facilitate the adoption of whole-genome sequencing with the launch of the TruSight™ Software Suite
Illumina, Inc. (NASDAQ:ILMN) has selected seven early-stage companies to join the first global cohort of Illumina Accelerator, the company creation engine focused on partnering with entrepreneurs
Illumina, Inc. (NASDAQ: ILMN) is enhancing its capabilities to analyze and interpret the data produced by its sequencing systems with the acquisition of BlueBee, a cloud-based software company that
Illumina, Inc. (NASDAQ: ILMN) today announced that the U.S. District Court for the Northern District of California issued a preliminary injunction order against several BGI companies, including MGI
Illumina, Inc. (NASDAQ: ILMN) is paving the way for large-scale, next-generation sequencing-based (NGS) COVID-19 testing. Today, the U.S. Food and Drug Administration (FDA) issued an Emergency Use
Illumina, Inc. (NASDAQ: ILMN) is committed to supporting the global, national and local relief efforts of our customers, employees and communities, as we unite to combat COVID-19. Giving back is in
Illumina (NASDAQ: ILMN) today announced the appointment of Alex Aravanis as Chief Technology Officer. Dr. Aravanis will be responsible for leading Illumina’s research and technology development
Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the first quarter of fiscal year 2020.
First quarter 2020 results:
Illumina, Inc. (NASDAQ: ILMN) is pleased to announce that the African Union Commission, on behalf of the Africa Center for Disease Control and Prevention (CDC), is receiving a $1.4 million donation
Illumina, Inc. (NASDAQ: ILMN) announces the Illumina SARS-CoV-2 Data Toolkit, a new suite of data analysis tools and workflow functionality for researchers working with the virus using
Illumina, Inc. (NASDAQ: ILMN) today announced preliminary revenue for the first quarter of fiscal year 2020 and withdrew its 2020 guidance.
Subject to quarter-end closing adjustments, the Company
Illumina, Inc. (NASDAQ: ILMN) today announced that it has filed a patent infringement suit relating to BGI’s “CoolMPS” sequencing products. The complaint was filed against BGI Genomics Co., Ltd
Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conferences and invited investors to participate via webcast.
SVB Leerink Global
